Nemtabrutinib
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematologic Malignancies
Conditions
Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
Trial Timeline
Apr 5, 2021 → Jan 4, 2029
NCT ID
NCT04728893About Nemtabrutinib
Nemtabrutinib is a phase 2 stage product being developed by Merck for Hematologic Malignancies. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04728893. Target conditions include Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06442436 | Phase 1 | Recruiting |
| NCT06772818 | Phase 1 | Completed |
| NCT06586671 | Phase 1 | Completed |
| NCT06772805 | Phase 1 | Completed |
| NCT05673460 | Phase 1 | Completed |
| NCT05347225 | Phase 1 | Active |
| NCT04728893 | Phase 2 | Recruiting |
| NCT03162536 | Phase 1/2 | Active |
Competing Products
20 competing products in Hematologic Malignancies
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| 120 mg LY2784544 | Eli Lilly | Phase 2 | 52 |
| RLYB116 for Injection | Rallybio | Phase 1 | 25 |
| DS3790a + Combination drug + Combination drug | Daiichi Sankyo | Phase 1/2 | 41 |
| Isavuconazole | Astellas Pharma | Phase 2 | 52 |
| isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oral | Astellas Pharma | Phase 1 | 33 |
| DSP-5336 + [14C]-DSP-5336 | Sumitomo Pharma | Phase 1 | 33 |
| BBI608 + Dexamethasone + Bortezomib + Imatinib + Ibrutinib | Sumitomo Pharma | Phase 1 | 33 |
| Venetoclax + ethinyl estradiol/levonorgestrel | AbbVie | Phase 1 | 33 |
| ABT-888 + Temozolomide | AbbVie | Phase 1 | 33 |
| ABBV-101 | AbbVie | Phase 1 | 33 |
| elotuzumab + lenalidomide + dexamethasone oral + dexamethasone injection | AbbVie | Phase 2 | 52 |
| Capivasertib + Rabeprazole | AstraZeneca | Phase 1 | 33 |
| AZD9829 + AZD9829 | AstraZeneca | Phase 1/2 | 41 |
| ridaforolimus | Merck | Phase 2 | 52 |
| Pembrolizumab/vibostolimab coformulation | Merck | Phase 2 | 52 |
| Nemtabrutinib | Merck | Phase 1 | 33 |
| Ondansetron + Aprepitant | Merck | Phase 2 | 52 |
| ARQ 621 | Merck | Phase 1 | 33 |
| Nemtabrutinib | Merck | Phase 1 | 33 |
| Pelabresib | Novartis | Phase 3 | 77 |